Free Trial

Enlivex Therapeutics (ENLV) Competitors

Enlivex Therapeutics logo
$1.05 0.00 (0.00%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ENLV vs. COYA, MGNX, TCRX, SRZN, ORMP, PLRX, ANEB, IPA, ANIX, and VIRI

Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Coya Therapeutics (COYA), MacroGenics (MGNX), TScan Therapeutics (TCRX), Surrozen (SRZN), Oramed Pharmaceuticals (ORMP), Pliant Therapeutics (PLRX), Anebulo Pharmaceuticals (ANEB), ImmunoPrecise Antibodies (IPA), Anixa Biosciences (ANIX), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry.

Enlivex Therapeutics vs. Its Competitors

Coya Therapeutics (NASDAQ:COYA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Coya Therapeutics has higher revenue and earnings than Enlivex Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coya Therapeutics$3.55M26.77-$14.88M-$1.24-4.58
Enlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.81

Coya Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 190.44%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 852.38%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Coya Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Coya Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Enlivex Therapeutics' return on equity of -58.31% beat Coya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coya TherapeuticsN/A -61.05% -53.61%
Enlivex Therapeutics N/A -58.31%-50.32%

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Coya Therapeutics had 5 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 8 mentions for Coya Therapeutics and 3 mentions for Enlivex Therapeutics. Coya Therapeutics' average media sentiment score of 0.19 beat Enlivex Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coya Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Enlivex Therapeutics beats Coya Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

MetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$24.83M$2.56B$5.78B$10.38B
Dividend YieldN/A57.29%5.74%4.64%
P/E Ratio-1.8123.0977.0826.78
Price / SalesN/A546.30507.10167.11
Price / CashN/A169.7137.1760.63
Price / Book1.055.3713.696.40
Net Income-$15.01M$32.95M$3.29B$271.62M
7 Day Performance-1.87%1.61%3.23%3.33%
1 Month PerformanceN/A7.76%8.37%10.15%
1 Year Performance-30.00%-2.89%82.31%31.19%

Enlivex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENLV
Enlivex Therapeutics
1.9721 of 5 stars
$1.05
flat
$10.00
+852.4%
-32.3%$24.83MN/A-1.8170
COYA
Coya Therapeutics
2.7792 of 5 stars
$5.68
-6.1%
$16.50
+190.5%
-5.3%$101.19M$3.55M-4.586Analyst Forecast
MGNX
MacroGenics
4.4845 of 5 stars
$1.56
-1.9%
$3.60
+130.8%
-47.6%$100.50M$149.96M-2.74430News Coverage
Analyst Upgrade
TCRX
TScan Therapeutics
2.6412 of 5 stars
$1.69
-4.0%
$7.80
+361.5%
-69.0%$99.88M$2.82M-1.55100Positive News
SRZN
Surrozen
2.1407 of 5 stars
$11.65
+0.7%
$38.50
+230.5%
+49.6%$99.12M$10.65M-0.8180
ORMP
Oramed Pharmaceuticals
0.3348 of 5 stars
$2.32
-3.7%
N/A+0.8%$98.82M$2M-6.6310
PLRX
Pliant Therapeutics
4.1448 of 5 stars
$1.53
-3.8%
$8.19
+435.1%
-88.1%$97.61M$1.58M-0.4590Positive News
ANEB
Anebulo Pharmaceuticals
1.6627 of 5 stars
$2.46
+3.8%
$5.50
+123.6%
+23.5%$97.37MN/A-9.464Upcoming Earnings
IPA
ImmunoPrecise Antibodies
2.5842 of 5 stars
$2.10
+8.5%
$4.00
+90.9%
+217.4%$96.68M$17.59M-3.0880Gap Up
ANIX
Anixa Biosciences
3.3446 of 5 stars
$3.52
+20.1%
$9.00
+155.7%
-2.3%$96.61MN/A-10.065High Trading Volume
VIRI
Virios Therapeutics
N/A$4.89
-0.1%
$5.00
+2.2%
+2,350.0%$94.17MN/A-18.115Gap Up

Related Companies and Tools


This page (NASDAQ:ENLV) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners